Is Palantir Stock Overvalued?
By every traditional yardstick, including a price‑to‑sales well above 100,…
Sell
20
PAVM Quote, Financials, Valuation and Earnings
Last price:
$0.64
Seasonality move
:
3.83%
Day range:
$0.64 - $0.68
52-week range:
$0.55 - $1.90
Dividend yield:
0%
P/E ratio:
0.91x
P/S ratio:
9.40x
P/B ratio:
0.59x
Volume:
156.3K
Avg. volume:
202K
1-year change:
-42.48%
Market cap:
$11M
Revenue:
$3M
EPS (TTM):
$0.70
Analysts' Opinion
-
Consensus RatingPAVmed has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $11.50, PAVmed has an estimated upside of 1701.1% from its current price of $0.64.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $0.64.
Fair Value
-
According to the consensus of 1 analyst, PAVmed has 1701.1% upside to fair value with a price target of $11.50 per share.
PAVM vs. S&P 500
-
Over the past 5 trading days, PAVmed has overperformed the S&P 500 by 1.46% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
PAVmed does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
PAVmed revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter PAVmed reported revenues of $8K.
Earnings Growth
-
PAVmed has grown year-over-year earnings for 0 quarters straight. In the most recent quarter PAVmed reported earnings per share of $0.34.
Enterprise value:
37.2M
EV / Invested capital:
0.78x
Price / LTM sales:
9.40x
EV / EBIT:
0.57x
EV / Revenue:
18.64x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.69x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
0.56x
Gross Profit (TTM):
-$1.1M
Return On Assets:
193.95%
Net Income Margin (TTM):
-1508.12%
Return On Equity:
--
Return On Invested Capital:
259.39%
Operating Margin:
-67850%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | $3M | $2M | $1M | $8K | |
| Gross Profit | -$4M | -$3.8M | -$1.1M | -$734K | -$28K | |
| Operating Income | -$91.9M | -$62.4M | -$35.8M | -$14M | -$5.4M | |
| EBITDA | -$101.4M | -$72.3M | $66.3M | -$17.9M | $18.7M | |
| Diluted EPS | -$14.81 | -$9.03 | $0.70 | -$2.62 | $0.34 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $50.5M | $71M | $53.8M | $29.6M | $3.6M | |
| Total Assets | $51.4M | $84.3M | $65.3M | $37.3M | $52.8M | |
| Current Liabilities | $3M | $17.5M | $50.5M | $55M | $9.8M | |
| Total Liabilities | $3.3M | $19.6M | $54.5M | $57.8M | $11.9M | |
| Total Equity | $48M | $64.7M | $10.8M | -$20.6M | $40.9M | |
| Total Debt | -- | -- | $44.3M | $45.5M | $6.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$75.1M | -$48.8M | -$22M | -$13.1M | -$1.6M | |
| Cash From Investing | -$3.2M | -$258K | -$16.1M | -$42K | -$6K | |
| Cash From Financing | $62.8M | $25.3M | $15.3M | $19M | $3.1M | |
| Free Cash Flow | -$76.1M | -$49M | -$22M | -$13.2M | -$1.6M | |
PAVM
Sector
Market Cap
$11M
$33.4M
Price % of 52-Week High
33.61%
46.84%
Dividend Yield
0%
0%
Shareholder Yield
28.91%
-0.6%
1-Year Price Total Return
-42.48%
-37.4%
Beta (5-Year)
1.065
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.65
200-day SMA
Sell
Level
$0.86
Bollinger Bands (100)
Sell
Level
0.63 - 0.75
Chaikin Money Flow
Sell
Level
-3.3M
20-day SMA
Sell
Level
$0.64
Relative Strength Index (RSI14)
Sell
Level
46.23
ADX Line
Buy
Level
10.42
Williams %R
Neutral
Level
-44.4349
50-day SMA
Sell
Level
$0.68
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
7.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-9.618)
Sell
CA Score
(Annual)
Level (-2.7545)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.5152)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
Stock Forecast FAQ
In the current month, PAVM has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PAVM average analyst price target in the past 3 months is $11.50.
-
Where Will PAVmed Stock Be In 1 Year?
According to analysts, the consensus estimate is that PAVmed share price will rise to $11.50 per share over the next 12 months.
-
What Do Analysts Say About PAVmed?
Analysts are divided on their view about PAVmed share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that PAVmed is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is PAVmed's Price Target?
The price target for PAVmed over the next 1-year time period is forecast to be $11.50 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PAVM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for PAVmed is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of PAVM?
You can purchase shares of PAVmed via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase PAVmed shares.
-
What Is The PAVmed Share Price Today?
PAVmed was last trading at $0.64 per share. This represents the most recent stock quote for PAVmed. Yesterday, PAVmed closed at $0.64 per share.
-
How To Buy PAVmed Stock Online?
In order to purchase PAVmed stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Gamestop’s Bitcoin Strategy Going To Succeed?
When GameStop (NYSE: GME) announced in Q1 that its board had…
How High Will Roku Stock Go?
Streaming software and hardware maker Roku (NASDAQ:ROKU) has seen its…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Sell
11
VEON alert for Jun 14
VEON [VEON] is down 18.57% over the past day.
Buy
74
DAVE alert for Jun 14
Dave [DAVE] is down 12.68% over the past day.
Buy
54
DAR alert for Jun 14
Darling Ingredients [DAR] is up 9.12% over the past day.
